[Editor’s note: 166 founders and leaders of biotech companies sent this letter to Nature Biotechnology.]
To the Editor:
We the undersigned, founders and leaders of biotech companies, write to express our deep concern and opposition to the executive order signed by President Donald Trump on January 27, 2017, barring the entry of citizens from seven countries into the United States.
The United States is the world’s greatest developer of medicines and new inventions to ameliorate and cure intractable diseases, a status achieved through massive investment in private and public companies, academia and R&D. Most importantly, our success has been founded on the creativity and dedication of our most precious resource—our people.
Our people include researchers, clinicians, entrepreneurs and business executives from all over the world. They are colleagues in our laboratories, management teams and boardrooms. They discover and develop therapies that drive US biomedical innovation and deliver new medicines to patients, not only in America, but also across the globe. And they start companies that drive the economic growth and employment provided by biotech. Many of our colleagues from abroad ultimately become Americans, all to the great benefit of the United States. Indeed, a study found that in 2014, 52% of the 69,000 biomedical researchers in the United States were foreign-born2.
At a stroke, the new administration has compromised years of investment in this national treasure. Our colleagues who are here on visas or are in global outposts are now fearful and uncertain of their status.
The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post: US immigration order strikes against biotech